Borohydride | 16971-29-2

• 英文名称: Borohydride
• 英文别名: boranuide
• CAS: 16971-29-2
• 化学式: BH4-
• 分子量: 14.85
• InChiKey: CROBTXVXNQNKKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.45
• 重原子数：
  1
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-methoxy-3-(4-methoxyphenyl)benzaldehyde 、 Borohydride 以 甲醇 为溶剂， 反应 16.0h， 以to afford 0.88 g of title compound的产率得到(4',6-dimethoxybiphenyl-3-yl)methanol
  参考文献：
  名称：

  Calcium receptor modulating agents

  摘要：

  该发明的化合物由以下一般结构或其药学上可接受的盐所代表，含有它们的组合物，其中变量的定义在此处，以及它们用于减少或抑制PTH分泌的用途，包括减少或抑制PTH分泌的方法和用于治疗或预防与骨疾病相关的疾病，如骨质疏松症，或与PTH过度分泌相关的疾病，如甲状旁腺功能亢进症的方法。该发明还涉及制造这种化合物的过程，以及在这种过程中有用的中间体。

  公开号：

  US06908935B2
• 作为试剂：
  描述：

  、 Borohydride 、 tert-butyl 4-(2-(tert-butoxycarbonyl)hydrazono)piperidine-1-carboxylate 、 水 在 Borohydride 、 四氢呋喃 、 乙醚 、 magnesium sulfate 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 tert-butyl 4-(2-tert-butoxycarbonylhydrazino)piperidine-1-carboxylate
  参考文献：
  名称：

  Phthalatyinone-piperidino-derivatives as pde4 inhibitors

  摘要：

  在化学式I中，给定的取代基具有描述中给出的含义，这些化合物是新颖的有效PDE4抑制剂。

  公开号：

  US20040067946A1

文献信息

• Thiazolidinedione Analogues For The Treatment Of Hypertension
  申请人：Colca Gerard R.

  公开号：US20100222399A1

  公开（公告）日：2010-09-02

  The present invention relates to thiazolidinedione analogues that are useful for treating hypertension, diabetes, and inflammatory diseases. Formula (I), wherein: each of R 1 and R 4 is independently selected from H, halo, aliphatic, and alkoxy, wherein the aliphatic and alkoxy are optionally substituted with 1-3 of halo; R 2 is halo, hydroxy, or optionally substituted aliphatic, and R′ 2 is H, or R 2 and R′ 2 together form oxo; R 3 is H; and Ring A is a phenyl.

  本发明涉及用于治疗高血压、糖尿病和炎症性疾病的噻唑烷二酮类似物。公式（I），其中：R1和R4各自独立选择自H、卤素、脂肪基和烷氧基，其中所述脂肪基和烷氧基可以选择性地被1-3个卤素取代；R2为卤素、羟基或可选择性取代的脂肪基，而R′2为H，或R2和R′2共同形成氧代；R3为H；环A为苯基。
• Photosensitizing transition metal complex and its use for photovoltaic cell
  申请人：Islam Ashraful

  公开号：US20050081911A1

  公开（公告）日：2005-04-21

  A photosensitizing transition metal complex of the formula (Ia) MLY 1 , (Ib) MLX 3 (Ic) MLY 2 X, (Id) MLY 3 X or (Ie) MLY 4 X in which M is a transition metal selected from ruthenium, osmium, iron, rhenium and technetium, preferably ruthenium or osmium. X is a co-ligand independently selected from NCS—, Cl—, Br—, I—, CN—, H 2 O; pyridine unsubstituted or substituted by at least one group selected from vinyl, primary, secondary or tertiary amine, OH and C 1-30 alkyl, preferably NSC and CN—; L is a tridentate polypyridine ligand, carrying at least one carboxylic, phosphoric acid or a chelating group and one substituted or unsubstituted alkyl group having 1 to 50 carbon atoms, substituted or unsubstituted alkylamide group having 2 to 30 carbon atoms or substituted or unsubstituted aralkyl group having 7 to 50 carbon atoms. A dye-sensitized electrode includes a substrate having an electrically conductive surface, an oxide semiconductor film formed on the conductive surface, and the above sensitizer of formula (Ia), (Ib), (Ic), (Id) or (Ie) as specified above, supported on the film. A solar cell includes the above electrode, a counter electrode, and an electrolyte deposited there between.

  公式（Ia）MLY1，（Ib）MLX3（Ic）MLY2X，（Id）MLY3X或（Ie）MLY4X的光敏过渡金属配合物，其中M是从钌，锇，铁，铼和锝中选择的过渡金属，优选钌或锇。X是一个配体，可以独立地选择从NCS-，Cl-，Br-，I-，CN-，H2O；吡啶未取代或取代至少一个选自乙烯基，一级，二级或三级胺，OH和C1-30烷基的基团，优选NSC和CN-；L是一个三齿多吡啶配体，携带至少一个羧酸，磷酸或螯合基团和一个取代或未取代的烷基，具有1至50个碳原子，取代或未取代的烷基酰胺基团，具有2至30个碳原子或取代或未取代的芳基烷基基团，具有7至50个碳原子。染料敏化电极包括具有电导表面的基底，形成在导电表面上的氧化物半导体薄膜以及上述配方（Ia），（Ib），（Ic），（Id）或（Ie）的敏化剂，支撑在薄膜上。太阳能电池包括上述电极，对电极和沉积在两者之间的电解质。
• Process for preparation of intermediates of carbocyclic nucleoside
  申请人：Bristol-Myers Squibb Company

  公开号：US05153352A1

  公开（公告）日：1992-10-06

  A compound of the formula: ##STR1## wherein A is a purin-9-yl group, a heterocyclic isostere of a purin-9-yl group, a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group; E is hydrogen, --CH.sub.2 OH or --OH; and G and D are independently selected from hydrogen, C.sub.1 to C.sub.10 alkyl, --OH, --CH.sub.2 OH, --CH.sub.2 OR.sub.20 wherein R.sub.20 is C.sub.1 to C.sub.6 alkyl, --CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is C.sub.1 to C.sub.10 alkyl, --CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 is the side chain of any of the naturally occuring amino acids and R.sub.23 is hydrogen or --C(O)CH(R.sub.24)(NH.sub.2) wherein R.sub.24 is the side chain of any of the naturally occuring amino acids, --CH.sub.1 SH, --Ch.sub.2 Cl, --Ch.sub.2 F, --CH.sub.2 Br, --CH.sub.2 I, --C(O)H, --CH.sub.2 CN, --CH.sub.2 N.sub.3, --CH.sub.2 NR.sub.1 R.sub.2, --CO.sub.2 R.sub.1, --CH.sub.2 CH.sub.2 OH, --CH.sub.2 CH.sub.2 OR.sub.20 wherein R.sub.20 is as defined above, --CH.sub.2 CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is as defined above, --CH.sub.2 CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 and R.sub.23 are as defined above, --CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2, --Ch.sub.2 OPO.sub.3 H.sub.2, --OCH.sub.2 PO.sub.3 H.sub.2 and --CH.sub.2 CO.sub.2 R.sub.3 wherein R.sub.1 and R.sub.2 are independently selected from hydrogen and C.sub.1 to C.sub.10 alkyl and R.sub.3 is hydrogen, C.sub.1 to C.sub.10 alkyl, carboxyalkyl or aminoalkyl; or a pharmaceutically acceptable salt thereof.

  该化合物的化学式为：##STR1## 其中A是嘌呤-9-基团，嘌呤-9-基团的杂环等价物，嘧啶-1-基团或嘧啶-1-基团的杂环等价物；E是氢，--CH.sub.2 OH或--OH；G和D是独立选择的氢，C.sub.1到C.sub.10烷基，--OH，--CH.sub.2 OH，--CH.sub.2 OR.sub.20，其中R.sub.20是C.sub.1到C.sub.6烷基，--CH.sub.2 OC(O)R.sub.21，其中R.sub.21是C.sub.1到C.sub.10烷基，--CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23)，其中R.sub.22是任何天然氨基酸的侧链，R.sub.23是氢或--C(O)CH(R.sub.24)(NH.sub.2)，其中R.sub.24是任何天然氨基酸的侧链，--CH.sub.1 SH，--Ch.sub.2 Cl，--Ch.sub.2 F，--CH.sub.2 Br，--CH.sub.2 I，--C(O)H，--CH.sub.2 CN，--CH.sub.2 N.sub.3，--CH.sub.2 NR.sub.1 R.sub.2，--CO.sub.2 R.sub.1，--CH.sub.2 CH.sub.2 OH，--CH.sub.2 CH.sub.2 OR.sub.20，其中R.sub.20如上所定义，--CH.sub.2 CH.sub.2 OC(O)R.sub.21，其中R.sub.21如上所定义，--CH.sub.2 CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23)，其中R.sub.22和R.sub.23如上所定义，--CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2，--Ch.sub.2 OPO.sub.3 H.sub.2，--OCH.sub.2 PO.sub.3 H.sub.2和--CH.sub.2 CO.sub.2 R.sub.3，其中R.sub.1和R.sub.2独立选择为氢和C.sub.1到C.sub.10烷基，R.sub.3为氢，C.sub.1到C.sub.10烷基，羧基烷基或氨基烷基；或其药学上可接受的盐。
• Piperidine-pyridazones and phthalazones as pde4 inhibitors
  申请人：Sterk Geert Jan

  公开号：US20060094710A1

  公开（公告）日：2006-05-04

  The compounds of a certain formula 1, in which the given substituents have the meanings as indicated in the description, are novel effective PDE4 inhibitors.

  某种化学式为1的化合物，其中给定的取代基具有描述中指定的含义，是新颖有效的PDE4抑制剂。
• Methods and intermediates for preparing cis-4-oxoazetidine intermediates
  申请人：SmithKline Corporation

  公开号：US04166816A1

  公开（公告）日：1979-09-04

  The stereospecific cycloaddition of nitrogen containing acetic acid halides or anhydrides with Schiff bases having a carbalkoxy group substituted on the methine carbon atom offers new intermediates and methods for preparing synthetic cephalosporin congeners having antibacterial activity.

  含氮乙酸卤代物或酐与在甲基碳原子上具有碳酰氧基的Schiff碱的立体特异性环加成提供了新的中间体和制备具有抗菌活性的合成头孢菌素类似物的方法。